Grever M - Search Results

1

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation.

Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, Gambril J, Kola-Kehinde O, Ruz P, Kalathoor S, Rogers K, Kittai A, Grever M, Awan F, Byrd JC, Woyach J, Bhat SA, Addison D. Chen ST, et al. Among authors: grever m. J Hematol Oncol. 2022 Jul 14;15(1):92. doi: 10.1186/s13045-022-01302-7. J Hematol Oncol. 2022. PMID: 35836241 Free PMC article.

2

Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy.

Grem JL, King SA, Chun HG, Grever MR. Grem JL, et al. Among authors: grever mr. Am J Hematol. 1991 Nov;38(3):245-7. doi: 10.1002/ajh.2830380320. Am J Hematol. 1991. PMID: 1951329

3

Introduction: chronic lymphocytic leukemia.

Byrd JC, Flinn IW, Grever MR. Byrd JC, et al. Among authors: grever mr. Semin Oncol. 1998 Feb;25(1):4-5. Semin Oncol. 1998. PMID: 9482520 No abstract available.

4

Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.

Byrd JC, Rai KR, Sausville EA, Grever MR. Byrd JC, et al. Among authors: grever mr. Semin Oncol. 1998 Feb;25(1):65-74. Semin Oncol. 1998. PMID: 9482528 Review.

5

Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.

Byrd JC, Grever MR, Waselenko JK, Willis CR, Park K, Goodrich A, Lucas MA, Shinn C, Flinn IW. Byrd JC, et al. Among authors: grever mr. Semin Oncol. 2000 Apr;27(2 Suppl 5):37-40. Semin Oncol. 2000. PMID: 10877050

6

Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.

Waselenko JK, Grever MR, Beer M, Lucas MA, Byrd JC. Waselenko JK, et al. Among authors: grever mr. Semin Oncol. 2000 Apr;27(2 Suppl 5):44-51. Semin Oncol. 2000. PMID: 10877052 Review.

7

Novel therapies for chronic lymphocytic leukemia in the 21st century.

Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Byrd JC, et al. Among authors: grever mr. Semin Oncol. 2000 Oct;27(5):587-97. Semin Oncol. 2000. PMID: 11049025 Review.

8

Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia.

Waselenko JK, Grever MR, Shinn CA, Flinn IW, Byrd JC. Waselenko JK, et al. Among authors: grever mr. Leuk Res. 2001 Jun;25(6):435-40. doi: 10.1016/s0145-2126(00)00106-5. Leuk Res. 2001. PMID: 11337014

9

UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.

Byrd JC, Shinn C, Willis CR, Flinn IW, Lehman T, Sausville E, Lucas D, Grever MR. Byrd JC, et al. Among authors: grever mr. Exp Hematol. 2001 Jun;29(6):703-8. doi: 10.1016/s0301-472x(01)00649-x. Exp Hematol. 2001. PMID: 11378265 Free article.

10

KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.

Byrd JC, Lucas DM, Mone AP, Kitner JB, Drabick JJ, Grever MR. Byrd JC, et al. Among authors: grever mr. Blood. 2003 Jun 1;101(11):4547-50. doi: 10.1182/blood-2002-08-2623. Epub 2003 Feb 20. Blood. 2003. PMID: 12595316 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

326 results

Search Page